Be part of the knowledge.™

Oncology and Hematology

838

LikeLikedUnlike

46-60 of 290

MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
- Kathleen Moore, MD, MS
  Peer
- Joyce F. Liu, MD, MPH
  Peer
0.50 credits 5 episodes
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
- Joyce F. Liu, MD, MPH
  Peer
0.50 program credits
MOA: CDH6-Targeted Antibody-Drug Conjugates
MinuteCE®
MOA: CDH6-Targeted Antibody-Drug Conjugates
- Kathleen Moore, MD, MS
  Peer
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
- Joyce F. Liu, MD, MPH
  Peer
0.50 program credits
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
- Kathleen Moore, MD, MS
  Peer
0.50 program credits
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
- Joyce F. Liu, MD, MPH
  Peer
- Kathleen Moore, MD, MS
  Peer
0.50 program credits
advertisement
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
CME/CE
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
- Joshua Richter, MD
  Peer
1.00 credits
MinuteCE®
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making  
- James M. Cleary, MD, PhD
  Peer
0.50 credits 4 episodes
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
MinuteCE®
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
- James M. Cleary, MD, PhD
  Peer
0.50 program credits
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers  
MinuteCE®
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers  
- James M. Cleary, MD, PhD
  Peer
0.50 program credits
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
- James M. Cleary, MD, PhD
  Peer
0.50 program credits
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
- James M. Cleary, MD, PhD
  Peer
0.50 program credits
advertisement
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
- Luis Paz-Ares, MD, PhD
  Peer
- Lauren A. Byers, MD
  Peer
0.50 credits 6 episodes
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
- Lauren A. Byers, MD
  Peer
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
- Luis Paz-Ares, MD, PhD
  Peer
- Lauren A. Byers, MD
  Peer
0.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended